Overview

Intranasal Bevacizumab for HHT-Related Epistaxis

Status:
Completed

Trial end date:
2020-01-23

Target enrollment:

Participant gender:

Summary

This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.

Phase:

Phase 4

Details

Lead Sponsor:

Stanford University

Treatments:

Bevacizumab